$39.49
2.125.67%
At Close: -
$39.49
00.00%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Mirum Pharmaceuticals
MIRMNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock, Analyst Ratings, Price Targets, Forecasts
Mirum Pharmaceuticals Inc has a consensus price target of $52.87 based on the ratings of 15 analysts. The high is $68 issued by JMP Securities on June 18, 2024. The low is $38 issued by Citigroup on May 9, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Stifel on July 8, 2024, June 28, 2024, and June 20, 2024, respectively. With an average price target of $66 between HC Wainwright & Co., HC Wainwright & Co., and Stifel, there's an implied 67.13% upside for Mirum Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Stifel
Citigroup
JP Morgan
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Mirum Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/08/2024 | Buy Now | 67.13% | HC Wainwright & Co. | Ed Arce | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 67.13% | HC Wainwright & Co. | Ed Arce | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 67.13% | Stifel | Dae Gon Ha | $48 → $66 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 62.07% | Citigroup | David Lebowitz | $38 → $64 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | -1.24% | JP Morgan | Jessica Fye | $31 → $39 | Maintains | Overweight | Get Alert |
| 06/18/2024 | Buy Now | 72.2% | JMP Securities | Jonathan Wolleben | $66 → $68 | Maintains | Market Outperform | Get Alert |
| 06/18/2024 | Buy Now | 44.34% | Morgan Stanley | Michael Ulz | $53 → $57 | Maintains | Overweight | Get Alert |
| 06/17/2024 | Buy Now | 67.13% | HC Wainwright & Co. | Ed Arce | $58 → $66 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | 21.55% | Stifel | Dae Gon Ha | $48 → $48 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | -1.24% | Baird | Brian Skorney | $34 → $39 | Maintains | Outperform | Get Alert |
| 06/07/2024 | Buy Now | 46.87% | HC Wainwright & Co. | Ed Arce | $58 → $58 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 46.87% | HC Wainwright & Co. | — | $58 → $58 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 34.21% | Morgan Stanley | Michael Ulz | $57 → $53 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 1.29% | Cantor Fitzgerald | Josh Schimmer | → $40 | Reiterates | Overweight → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 46.87% | HC Wainwright & Co. | Ed Arce | → $58 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 67.13% | JMP Securities | Jonathan Wolleben | $72 → $66 | Maintains | Market Outperform | Get Alert |
| 05/09/2024 | Buy Now | -3.77% | Citigroup | David Lebovitz | $37 → $38 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 21.55% | Stifel | Dae Gon Ha | → $48 | Initiates | → Buy | Get Alert |
| 04/02/2024 | Buy Now | 46.87% | HC Wainwright & Co. | Ed Arce | $58 → $58 | Maintains | Buy | Get Alert |
| 03/18/2024 | Buy Now | 8.89% | Leerink Partners | Mani Foroohar | $44 → $43 | Maintains | Outperform | Get Alert |
| 03/14/2024 | Buy Now | 82.32% | JMP Securities | Jonathan Wolleben | $69 → $72 | Maintains | Outperform | Get Alert |
| 03/14/2024 | Buy Now | 46.87% | HC Wainwright & Co. | Ed Arce | $45 → $58 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 1.29% | Cantor Fitzgerald | Josh Schimmer | $35 → $40 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 13.95% | HC Wainwright & Co. | Ed Arce | $58 → $45 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 74.73% | JMP Securities | Jonathan Wolleben | $64 → $69 | Maintains | Market Outperform | Get Alert |
| 02/29/2024 | Buy Now | -11.37% | Cantor Fitzgerald | Josh Schimmer | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 01/11/2024 | Buy Now | 62.07% | JMP Securities | Jonathan Wolleben | → $64 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/19/2023 | Buy Now | 62.07% | Raymond James | Steven Seedhouse | $78 → $64 | Maintains | Strong Buy | Get Alert |
| 12/18/2023 | Buy Now | 46.87% | HC Wainwright & Co. | Ed Arce | $60 → $58 | Maintains | Buy | Get Alert |
| 11/27/2023 | Buy Now | 26.61% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2023 | Buy Now | -6.31% | JP Morgan | Jessica Fye | → $37 | Reinstates | → Overweight | Get Alert |
| 11/15/2023 | Buy Now | 26.61% | Cantor Fitzgerald | Joshua Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/13/2023 | Buy Now | 51.94% | Morgan Stanley | Michael Ulz | → $60 | Initiates | → Overweight | Get Alert |
| 11/03/2023 | Buy Now | 51.94% | HC Wainwright & Co. | Ed Arce | $63 → $60 | Maintains | Buy | Get Alert |
| 10/24/2023 | Buy Now | 26.61% | Cantor Fitzgerald | Joshua Schimmer | → $50 | Initiates | → Overweight | Get Alert |
| 10/18/2023 | Buy Now | 77.26% | JMP Securities | Jonathan Wolleben | → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 10/18/2023 | Buy Now | 94.99% | Raymond James | Steven Seedhouse | $84 → $77 | Maintains | Strong Buy | Get Alert |
| 10/17/2023 | Buy Now | 57% | Evercore ISI Group | Gavin Clark-Gartner | → $62 | Reinstates | → Outperform | Get Alert |
| 10/09/2023 | Buy Now | 77.26% | JMP Securities | Jonathan Wolleben | → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/20/2023 | Buy Now | 77.26% | JMP Securities | Jonathan Wolleben | → $70 | Initiates | → Market Outperform | Get Alert |
| 09/13/2023 | Buy Now | 59.53% | HC Wainwright & Co. | Ed Arce | → $63 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | 112.71% | Raymond James | Steven Seedhouse | $79 → $84 | Maintains | Strong Buy | Get Alert |
| 08/04/2023 | Buy Now | 59.53% | HC Wainwright & Co. | Ed Arce | → $63 | Reiterates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | 100.05% | Raymond James | Steven Seedhouse | $82 → $79 | Maintains | Strong Buy | Get Alert |
| 07/18/2023 | Buy Now | 59.53% | HC Wainwright & Co. | Ed Arce | $61 → $63 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 107.65% | Raymond James | Steven Seedhouse | $81 → $82 | Maintains | Strong Buy | Get Alert |
| 06/15/2023 | Buy Now | 54.47% | HC Wainwright & Co. | Ed Arce | → $61 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 54.47% | HC Wainwright & Co. | Ed Arce | → $61 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 54.47% | HC Wainwright & Co. | Ed Arce | → $61 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 105.12% | Raymond James | Steven Seedhouse | $83 → $81 | Maintains | Strong Buy | Get Alert |
| 04/06/2023 | Buy Now | 54.47% | HC Wainwright & Co. | Ed Arce | → $61 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 54.47% | HC Wainwright & Co. | Ed Arce | → $61 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 54.47% | HC Wainwright & Co. | Ed Arce | → $61 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 110.18% | Raymond James | Steven Seedhouse | $84 → $83 | Maintains | Strong Buy | Get Alert |
| 02/15/2023 | Buy Now | 54.47% | HC Wainwright & Co. | Ed Arce | $69 → $61 | Reiterates | → Buy | Get Alert |
| 01/10/2023 | Buy Now | 112.71% | Raymond James | Steven Seedhouse | $88 → $84 | Maintains | Strong Buy | Get Alert |
| 01/10/2023 | Buy Now | -1.24% | SVB Leerink | Mani Foroohar | $50 → $39 | Maintains | Outperform | Get Alert |
| 12/14/2022 | Buy Now | 26.61% | SVB Leerink | Mani Foroohar | $49 → $50 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 74.73% | HC Wainwright & Co. | Ed Arce | $68 → $69 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | -13.9% | Citigroup | David Lebowitz | $38 → $34 | Maintains | Buy | Get Alert |
| 10/25/2022 | Buy Now | 122.84% | Raymond James | Steven Seedhouse | $75 → $88 | Maintains | Strong Buy | Get Alert |
| 10/25/2022 | Buy Now | 72.2% | HC Wainwright & Co. | Ed Arce | $63 → $68 | Maintains | Buy | Get Alert |
| 09/01/2022 | Buy Now | -3.77% | Citigroup | David Lebowitz | → $38 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 31.68% | SVB Leerink | Mani Foroohar | $50 → $52 | Maintains | Outperform | Get Alert |
| 05/23/2022 | Buy Now | 74.73% | HC Wainwright & Co. | Ed Arce | $64 → $69 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 89.92% | Raymond James | Steven Seedhouse | $74 → $75 | Maintains | Strong Buy | Get Alert |
| 04/26/2022 | Buy Now | 24.08% | SVB Leerink | Mani Foroohar | $46 → $49 | Maintains | Outperform | Get Alert |
| 03/11/2022 | Buy Now | 87.39% | Raymond James | Steven Seedhouse | $70 → $74 | Maintains | Strong Buy | Get Alert |
| 01/28/2022 | Buy Now | 16.49% | SVB Leerink | Mani Foroohar | $42 → $46 | Maintains | Outperform | Get Alert |
| 01/12/2022 | Buy Now | 77.26% | Raymond James | Steven Seedhouse | $69 → $70 | Maintains | Strong Buy | Get Alert |
| 09/30/2021 | Buy Now | 62.07% | HC Wainwright & Co. | Ed Arce | — | Maintains | Buy | Get Alert |
| 09/30/2021 | Buy Now | 74.73% | Raymond James | Steven Seedhouse | — | Maintains | Strong Buy | Get Alert |
| 09/30/2021 | Buy Now | 3.82% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
| 09/20/2021 | Buy Now | -24.03% | JP Morgan | Jessica Fye | — | Initiates | → Overweight | Get Alert |
| 09/14/2021 | Buy Now | 29.15% | Raymond James | Steven Seedhouse | — | Maintains | Strong Buy | Get Alert |
| 09/14/2021 | Buy Now | 29.15% | HC Wainwright & Co. | Ed Arce | — | Maintains | Buy | Get Alert |
| 09/13/2021 | Buy Now | -18.97% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
| 08/06/2021 | Buy Now | -16.43% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Mirum Pharmaceuticals (MIRM) stock?
The latest price target for Mirum Pharmaceuticals (NASDAQ:MIRM) was reported by HC Wainwright & Co. on July 8, 2024. The analyst firm set a price target for $66.00 expecting MIRM to rise to within 12 months (a possible 67.13% upside). 44 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mirum Pharmaceuticals (MIRM)?
The latest analyst rating for Mirum Pharmaceuticals (NASDAQ:MIRM) was provided by HC Wainwright & Co., and Mirum Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Mirum Pharmaceuticals (MIRM)?
There is no last upgrade for Mirum Pharmaceuticals
When was the last downgrade for Mirum Pharmaceuticals (MIRM)?
There is no last downgrade for Mirum Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Mirum Pharmaceuticals (MIRM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mirum Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mirum Pharmaceuticals was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.
Is the Analyst Rating Mirum Pharmaceuticals (MIRM) correct?
While ratings are subjective and will change, the latest Mirum Pharmaceuticals (MIRM) rating was a reiterated with a price target of $66.00 to $66.00. The current price Mirum Pharmaceuticals (MIRM) is trading at is $39.49, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.